NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: HeartBeam's Participation in JP Morgan 2026 Healthcare Conference and FDA-Cleared Cardiac Technology
TL;DR
HeartBeam's FDA-cleared cable-free ECG technology offers investors early access to a portable cardiac monitoring market poised for growth ahead of its Q1 2026 commercial launch.
HeartBeam's system uses 5 electrodes to capture 3D ECG signals, synthesizing them into a 12-lead ECG via patented software cleared by the FDA for arrhythmia assessment.
This portable technology enables cardiac monitoring outside medical facilities, potentially improving early detection and access to care for patients with heart conditions.
HeartBeam is creating the first cable-free device that captures 3D heart signals and transforms them into a 12-lead ECG using over 20 patented technologies.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam (NASDAQ: BEAT) announced it will attend the JP Morgan 2026 Annual Healthcare Conference where company executives will meet with investors and partners to discuss its FDA-cleared cable-free 12-lead ECG synthesis software for arrhythmia assessment.
The conference will be held January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, with HeartBeam executives available for meetings January 12-14.
Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will represent HeartBeam at the conference.
HeartBeam's patented cable-free 12-lead electrocardiogram synthesis software, which received FDA 510(k) clearance for arrhythmia assessment and synthesizes a 12-lead ECG from 3D signals collected from three non-coplanar directions.
The 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received clearance in December 2025.
HeartBeam plans a limited U.S. commercial launch in Q1 2026, following the recent FDA clearance.
HeartBeam creates the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
The synthesized 12-Lead ECG output is intended for manual assessment of normal sinus rhythm and non-life-threatening arrhythmias including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex.
The technology is not intended for assessment of life-threatening conditions, other atrial/ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, localization of arrhythmia foci, ECG wave abnormalities, or any other disorders beyond those specifically cleared.
For additional information, visit HeartBeam.com or view the full press release at https://nnw.fm/zvmUc.
Curated from NewMediaWire
